1h Free Analyst Time
This report offers market size & forecast data for the global premature ejaculation therapeutics market. The revenue generated from the sale of drugs, including off-label products, is included in the report. The revenue generated from the devices used to manage premature ejaculation, physicians’ fees, and other service-related costs is excluded from the report's scope. This report provides a comprehensive and current market scenario of the global premature ejaculation therapeutics market, including the global premature ejaculation therapeutics market size, anticipated market forecast, relevant market segmentations, and industry trends. Speak directly to the analyst to clarify any post sales queries you may have.
The study considers a detailed scenario of the present global premature ejaculation therapeutics market and its market dynamics for 2024−2029. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent players operating in the market.
KEY HIGHLIGHTS
- The global premature ejaculation therapeutics market was valued at $2,456.71 million in 2023 and is expected to reach $4,062.34 million by 2029, growing at a CAGR of 8.74%. The market growth is mainly attributed to the rising prevalence of premature ejaculation among men globally.
- In 2023, North America and Europe dominated the market with a market share of 43.79% and 25.02%, respectively. APAC is expected to be the fastest-growing market for premature ejaculation (PE) therapeutics in terms of revenue during the forecast period, with a CAGR of 10.56%.
- By drug class, the Selective Serotonin Reuptake Inhibitors (SSRIs) segment was valued at $1,064.41 million in 2023 and is expected to reach $1,759.00 million by 2029, growing at a CAGR of 8.73%. The increased recommendation of SSRIs by healthcare professionals is one of the key factors for the growth of the segment worldwide. SSRIs are considered effective drugs for the treatment of premature ejaculation therapeutics market.
- By Route of Administration, the oral therapeutics segment was valued at $1,847.37 million in 2023 and is expected to reach $2,975.67 million by 2029, growing at a CAGR of 8.27%. The increased recommendation of oral therapeutics by healthcare professionals is one of the key factors for the growth of the segment worldwide. Also, the growing pervasiveness of premature ejaculation and the increasing uptake of generic off-label medications are the key factors enabling the growth of the oral ROA segment.
- By age group, the people aged below 45 years segment was valued at $1,519.11 million in 2023 and is expected to reach $2,536.12 million by 2029, growing at a CAGR of 8.92%. The rise in the prevalence of premature ejaculation in the younger population is the major factor contributing to the market growth during the forecast period.
- Plethora Solutions, Pfizer, Eli Lilly and Company, GSK plc, and the Menarini group are some leading players currently dominating the global premature ejaculation therapeutics market. The major players focus on strategic acquisitions and collaborations with emerging players to enter the premature ejaculation therapeutics market and access commercially launched products.
VENDORS LIST
- Plethora Solutions
- Pfizer
- Absorption Pharmaceuticals
- Eli Lilly and Company
- GSK plc
- Bayer AG
- MidasCare
- Pound International
- Momentum Management
- Reckitt Benckiser Group
- Recordati
- Royalty Pharma
- Shibari
- Johnson & Johnson
- The Menarini Group
- Futura Medical
- Niksan Pharmaceuticals
- Amneal Pharmaceuticals
PRODUCT SEGMENTATION & FORECAST
- Drug Class
- Selective Serotonin Re-uptake Inhibitors (SSRIs)
- Phosphodiesterase type 5 (PDE5) inhibitors
- Anesthetic Agents
- Others
- Route of Administration
- Oral Therapeutics
- Topical Therapeutics
- Age Group
- Below 45 years
- Above 45 years
MARKET STRUCTURE
- Market Dynamics
- Competitive Landscape of PE Therapeutics Market
- Key Vendors
- Other Prominent Vendors
APPENDIX
- Research Methodology
- Abbreviations
- About the Analyst
Table of Contents
Chapter - 1: Pe Therapeutics Market Overview
Chapter - 2: Pe Therapeutics Market
Chapter - 3: Pe Therapeutics Market Segmentation Data
Chapter - 4: Key Regions Overview
Chapter - 5: Pe Therapeutics Market Prospects & Opportunities
Chapter - 6: Pe Therapeutics Industry Overview
Chapter - 7: Appendix
List of Exhibits
List of Tables
Companies Mentioned
- Plethora Solutions
- Pfizer
- Absorption Pharmaceuticals
- Eli Lilly and Company
- GSK plc
- Bayer AG
- MidasCare
- Pound International
- Momentum Management
- Reckitt Benckiser Group
- Recordati
- Royalty Pharma
- Shibari
- Johnson & Johnson
- The Menarini Group
- Futura Medical
- Niksan Pharmaceuticals
- Amneal Pharmaceuticals
Methodology
Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.
Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 109 |
| Published | December 2023 |
| Forecast Period | 2023 - 2029 |
| Estimated Market Value ( USD | $ 2.46 Billion |
| Forecasted Market Value ( USD | $ 4.06 Billion |
| Compound Annual Growth Rate | 8.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 18 |
